Biotricity (Biotricity) Cash And Cash Equivalents : $0.09 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biotricity Cash And Cash Equivalents?

Biotricity's quarterly cash and cash equivalents increased from Jun. 2023 ($0.05 Mil) to Sep. 2023 ($1.20 Mil) but then stayed the same from Sep. 2023 ($1.20 Mil) to Dec. 2023 ($0.09 Mil).

Biotricity's annual cash and cash equivalents increased from Mar. 2021 ($2.20 Mil) to Mar. 2022 ($12.07 Mil) but then declined from Mar. 2022 ($12.07 Mil) to Mar. 2023 ($0.57 Mil).

Biotricity Cash And Cash Equivalents Historical Data

The historical data trend for Biotricity's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity Cash And Cash Equivalents Chart

Biotricity Annual Data

Trend

Aug14

Aug15

Dec16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.06

0.95

2.20

12.07

0.57

Biotricity Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.45	0.57	0.05	1.20	0.09

Biotricity Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Biotricity (NAS:BTCY) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Biotricity Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Biotricity's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotricity (Biotricity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

QB00:Germany

Address

275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065

Website

https://www.biotricity.com

Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.

Executives

Chester P White	director	447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon	director	1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq	director, 10 percent owner, officer: CEO and Chairman of the Board	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou	officer: Chief Financial Officer	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065